(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
22 March 2012 (22.03.2012)

PCT

(10) International Publication Number
WO 2012/035158 A1

(51) International Patent Classification:
C07D 241/26 (2006.01) *A61K 31/497* (2006.01)
C07D 403/12 (2006.01) *A61P 11/00* (2006.01)
C07D 487/10 (2006.01)

(21) International Application Number:
PCT/EP2011/066151

(22) International Filing Date:
16 September 2011 (16.09.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/383,985 17 September 2010 (17.09.2010) US
61/524,495 17 August 2011 (17.08.2011) US

(71) Applicant *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BHALAY, Gurdip** [GB/GB]; Novartis Pharmaceuticals UK Limited, Wimblehurst Road, Horsham, West Sussex Sussex RH12 5AB (GB). **EDWARDS, Lee** [GB/GB]; Novartis Pharmaceuticals UK Limited, Wimblehurst Road, Horsham, West Sussex Sussex RH12 5AB (GB). **HOWSHAM, Catherine** [GB/GB]; Novartis Pharmaceuticals UK Limited, Wimblehurst Road, Horsham, West Sussex Sussex RH12 5AB (GB). **HUNT, Peter** [GB/GB]; Novartis Pharmaceuticals UK Limited, Wimblehurst Road, Horsham, West Sussex Sussex RH12 5AB (GB). **SMITH, Nichola** [GB/GB]; Novartis Pharmaceuticals UK Limited, Wimblehurst Road, Horsham, West Sussex Sussex RH12 5AB (GB).

(74) Agent: **MUELLER, Philippe**; Novartis Pharma Ag, Patent Department, CH-4002 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

WO 2012/035158 A1

(54) Title: PYRAZINE DERIVATIVES AS ENAC BLOCKERS



(I)

(57) Abstract: Compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, and R^{10} have the meanings as indicated in the specification, are useful for treating diseases mediated by blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.